There is no disputing that Nike (NKE) has experienced its fair share of challenges in recent years. Soft demand for sportswear in key markets and an increasingly competitive industry has resulted in lacklustre top line growth. In FY2020 and FY2024, for example, NKE reported a decline in YoY sales growth. On the Q4 2024 earnings [...]
My underlying reason for performing this 2024 Mid Year FFJ Portfolio Review is to get a high level overview of all our investments. I manage a total of 19 accounts held at two discount brokers. Unless I perform these reviews, I can not easily determine what percentage of our total holdings is held in each [...]
This FFJ Portfolio - June 2024 report recaps my investment activity during the month. In my June 11 FFJ Portfolio Adjustments Before Capital Gains Tax Changes Arrive, I disclose multiple changes to the FFJ Portfolio. After these changes, drawing a direct comparison with prior periods is of little value. I, therefore, am no longer providing [...]
I last reviewed Alimentation Couche-Tard (ATD.to) in this December 7, 2023 post. At the time, the most current financial information was for Q2 and YTD2024. We now have ATD's Q4 and FY2024 results which has prompted me to revisit this company. When I wrote my prior post, I held 1227 ATD shares in one of [...]
My analysis of Brown-Forman is accessible through my guest post at Dividend Power. When I wrote my December 13, 2016 Brown-Forman Corporation Stock Analysis: Enriching Life? Not Lately! post, the company's slogan was Enriching Life. Now, the company's slogan is Nothing Better. If Brown-Forman (BF) is talking about its investment performance, nothing could be further [...]
In my May 20 West Pharmaceutical (WST) post, I disclosed the purchase of an additional 100 shares @ ~$345.56 in the FFJ Portfolio on May 20 after listening to WST's presentation at BofA's Health Care Conference 2024. Nothing has materially changed following that purchase. WST's share price has, however, experienced subsequent weakness thus leading me [...]
The purpose of this brief post is to disclose the FFJ Portfolio adjustments I have made before capital gains tax changes arrive in Canada. In addition, I disclose the purchase of additional CME Group (CME) shares. On April 16, 2024, the Canadian federal government proposed an increase to the capital gains inclusion rate as part [...]
I will not touch TransDigm Group (TDG) despite it having been an immensely rewarding investment since going public in 2006. Not only is its lofty valuation an area of concern, its liberal use of debt is well beyond my risk tolerance. On occasion, I will invest in a company whose leverage is elevated because it [...]
This FFJ Portfolio - May 2024 report recaps my investment activity during the month. In several recent posts that are accessible through the FFJ Archives, I have disclosed my decision to drastically reduce my exposure to Canadian companies. This will lead to a perfectly acceptable significant reduction in my Canadian dividend income starting in June. [...]
Heed the advice of Charlie Munger. Stop active trading! The Big Money Is Not In The Buying And The Selling But In The Waiting In my recent Focus On Total Shareholder Return post, I discussed why fixating on dividend metrics to make investment decisions is ridiculous. In this post, I touch upon why you should [...]